Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01467076 · ClinicalTrials.gov registry record · Phase 2
Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)
A Phase 2 study, sponsored by NICHD Neonatal Research Network.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01467076 is a Phase 2 study that was terminated before completion, run by NICHD Neonatal Research Network. The registered enrollment target is 7 participants.
The verdict
NCT01467076, a Phase 2 study, was terminated before completion, sponsored by NICHD Neonatal Research Network.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is a randomized controlled trial (RCT) on the use of Inhaled prostaglandin E1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure (NHRF). Fifty patients recruited at 10 high volume sites within the NICHD Neonatal Research Network will constitute a pilot sample to evaluate the feasibility and safety of prolonged IPGE1 administration and determination of optimal dose. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours and compared with placebo. Once feasibility and safety of IPGE1 administered over 72 hours has been demonstrated in the pilot trial, a full scale randomized controlled trial will be planned.
Interventions
- DRUG Aerosolized Normal Saline
- DRUG Inhaled PGE1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01467076
The ClinicalTrials.gov registry entry for NCT01467076 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 61 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aerosolized Normal Saline is the first listed.
NCT01467076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01467076 about?
NCT01467076 is a clinical study titled "Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)". This is a randomized controlled trial (RCT) on the use of Inhaled prostaglandin E1 (IPGE1) in Neonatal Hypoxemic Respiratory Failure (NHRF). Fifty patients recruited at 10 high volume sites within the NICHD Neonatal Research Network will constitute a pilot sample to evaluate the feasibility and safe...
What is the current status of trial NCT01467076?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2011-11. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01467076?
The interventions under investigation include: Aerosolized Normal Saline (DRUG), Inhaled PGE1 (DRUG).
Who is sponsoring clinical trial NCT01467076?
This trial is sponsored by NICHD Neonatal Research Network, which has 61 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.